Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Silodosin vs Tamsulosin for Ureteral Stones in Chinese Patients
NCT05570084Phase 3Unknown
- Sponsor
- Princess Margaret Cancer Centre
- Start
- May 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of silodosin in ureteral stone, sponsored by Princess Margaret Cancer Centre. Primary endpoint: Stone free rate at 2 weeks. Status: unknown.
02
Drugs
silodosin
03
Conditions
ureteral stone
Beyond the preview
Go deeper on NCT05570084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05570084.